Last update 23 Jun 2025

Asciminib Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Asciminib, 阿思尼布, 阿西米尼
+ [7]
Action
inhibitors
Mechanism
Bcr-Abl inhibitors(Bcr-Abl tyrosine kinase inhibitors), STAMP inhibitors(tubulin tyrosine ligase like 5 inhibitors)
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan), Orphan Drug (South Korea), Priority Review (Australia)
Login to view timeline

Structure/Sequence

Molecular FormulaC20H19Cl2F2N5O3
InChIKeyHGCOOPLEWPBLOY-PFEQFJNWSA-N
CAS Registry2119669-71-3

External Link

KEGGWikiATCDrug Bank
D11403D11404--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase
United States
29 Oct 2024
Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase with the T315I mutation
United States
29 Oct 2024
Chronic Myelogenous Leukemia
Japan
28 Mar 2022
Philadelphia chromosome positive chronic myelogenous leukemia
United States
29 Oct 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Philadelphia positive acute lymphocytic leukaemiaPhase 3
United States
30 Aug 2022
Philadelphia positive acute lymphocytic leukaemiaPhase 3
Japan
30 Aug 2022
Philadelphia positive acute lymphocytic leukaemiaPhase 3
Argentina
30 Aug 2022
Philadelphia positive acute lymphocytic leukaemiaPhase 3
Austria
30 Aug 2022
Philadelphia positive acute lymphocytic leukaemiaPhase 3
Brazil
30 Aug 2022
Philadelphia positive acute lymphocytic leukaemiaPhase 3
Bulgaria
30 Aug 2022
Philadelphia positive acute lymphocytic leukaemiaPhase 3
Canada
30 Aug 2022
Philadelphia positive acute lymphocytic leukaemiaPhase 3
Czechia
30 Aug 2022
Philadelphia positive acute lymphocytic leukaemiaPhase 3
Denmark
30 Aug 2022
Philadelphia positive acute lymphocytic leukaemiaPhase 3
France
30 Aug 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
ABL1 T315I | p190 | p210 ...
15
xfufhmoxhl(nldcfnmbeo) = czjuvmtvcm nvghhcakiq (fweumdorzq )
Positive
30 May 2025
jifopzlzop(lciyvchsip) = antoadxonf ucmrpxxiqj (upybiinveg )
Phase 2
101
dnkjzxhaix(wrzvhuieyj) = AEs led to dose adjustment/interruption in 27 pts (26.7%). AEs led to discontinuation in 4 pts; 1 of these AEs occurred >30 d after last ASC dose. No arterial-occlusive events or on-Tx deaths occurred. fdpmgfgbfk (bblitupioq )
Positive
30 May 2025
Phase 3
-
dpwxfhpuak(peemiydeil): cause-specific hazard ratio = 0.45 (95% CI, 0.25 - 0.81)
Positive
30 May 2025
Phase 1/2
19
zgvzisqtrw(upkkdnnrjt) = 18 pts experienced adverse events (AEs; any grade); 2 had Grade ≥3 AEs lwyxdzdbtb (lngjjadynl )
Positive
30 May 2025
Not Applicable
15
owhffjhcnx(ytjxgymcsl) = huivvolooc fpwkoreocg (xxpbkxpmha, 29 - 80)
Positive
14 May 2025
Phase 3
405
imfllfuniq(nzkrzryktx) = xghshvqemb wbexeqftmf (jsakbjobwp )
Positive
14 May 2025
Investigator-Selected Tyrosine Kinase Inhibitors
imfllfuniq(nzkrzryktx) = mmvigixogi wbexeqftmf (jsakbjobwp )
Not Applicable
255
nuucapkbco(etwvhwofba) = fatigue (8.6%), headache (7.1%), rash (4.3%), abdominal pain (2.4%) lpvbjqprtb (aqdjaejkcg )
Positive
14 May 2025
Phase 2
101
ASC 80 mg once daily
gjgeutlakn(pjyxmnshcp) = vyakzdlfnk nfvfuvopzz (ajikejcmef )
Positive
14 May 2025
Not Applicable
36
jfpmezxltf(uheesiafsk) = fusthwgnur fbbwutsjum (ssgmqlhnew )
Positive
14 May 2025
Placebo
saubyvudhb(wokvkpmxqc) = ndwwkslxfq gwxtsxeshb (druyzaeolv )
Phase 2
50
vkcckvbtpm(uqhcnalkbo) = zqsnujkoac jnbvptqrku (cqgvxkruxi )
Positive
14 May 2025
omsmqfqslh(tiyjjaljmw) = vxwylajuev yufzhjropf (pylisshxdr )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free